Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ORIC-101 in Healthy Adults
NCT03324555Phase 1Completed
- Sponsor
- ORIC Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ORIC-101 in solid tumor, sponsored by ORIC Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Oct 2017; status: completed.
02
Drugs
ORIC-101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03324555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03324555.